^
    Apply
    Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer (REMAIN) (NCT06029270)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    07/15/2024
    Primary completion :
    04/30/2029
    Completion :
    04/30/2029
    PD-L1 • LAG3
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • gemcitabine • relatlimab (BMS-986016) • ABP 206 (nivolumab biosimilar)
    A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (NCT05852691)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/19/2025
    Initiation :
    07/18/2023
    Primary completion :
    12/24/2026
    Completion :
    12/24/2026
    HER-2 • PD-L1 • ER • CD4
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • albumin-bound paclitaxel • tobemstomig (RG6139)
    A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% (RELATIVITY-1093) (NCT06561386)
    Phase 3
    Bristol-Myers Squibb
    Recruiting
    Last update posted :
    02/19/2025
    Initiation :
    10/07/2024
    Primary completion :
    07/30/2030
    Completion :
    11/11/2033
    PD-L1
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • cisplatin • carboplatin • pemetrexed • Opdualag (nivolumab/relatlimab-rmbw)
    Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (BGB-900-102) (NCT03744468)
    Phase 1/2
    BeiGene
    Completed
    Last update posted :
    02/14/2025
    Initiation :
    11/13/2018
    Primary completion :
    02/06/2025
    Completion :
    02/06/2025
    PD-L1
    |
    PD-L1 expression
    |
    Tevimbra (tislelizumab-jsgr) • alcestobart (LBL-007) • surzebiclimab (BGB-A425)
    Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma (CA224-094) (NCT04552223)
    Phase 2
    Jose Lutzky, MD
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    11/10/2020
    Primary completion :
    01/04/2024
    Completion :
    01/04/2026
    LAG3 • CTLA4
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab (GIANT) (NCT06816927)
    Phase 2
    Duke University
    Not yet recruiting
    Last update posted :
    02/10/2025
    Initiation :
    06/01/2025
    Primary completion :
    06/01/2029
    Completion :
    06/01/2031
    MGMT
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) (KEYMAKER-U04 Substudy) (NCT05845814)
    Phase 1/2
    Merck Sharp & Dohme LLC
    Active, not recruiting
    Last update posted :
    02/10/2025
    Initiation :
    06/23/2023
    Primary completion :
    05/31/2027
    Completion :
    05/31/2027
    PD-L1
    |
    Padcev (enfortumab vedotin-ejfv) • favezelimab/pembrolizumab (MK-4280A) • vibostolimab/pembrolizumab (MK-7684A)
    A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer (NCT05645692)
    Phase 2
    Hoffmann-La Roche
    Active, not recruiting
    Last update posted :
    02/06/2025
    Initiation :
    04/13/2023
    Primary completion :
    12/30/2026
    Completion :
    12/30/2026
    PD-L1
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer (NCT05800015)
    Phase 2/3
    Regeneron Pharmaceuticals
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    08/08/2023
    Primary completion :
    01/16/2030
    Completion :
    12/23/2031
    PD-L1
    |
    PD-L1 expression
    |
    cisplatin • carboplatin • paclitaxel • pemetrexed • Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    ARID1A and/or KDM6A Mutation and CXCL13 Expression (NCT04953104)
    Phase 2
    M.D. Anderson Cancer Center
    Recruiting
    Last update posted :
    01/29/2025
    Initiation :
    09/21/2021
    Primary completion :
    12/31/2026
    Completion :
    12/31/2026
    ARID1A • CXCL13
    |
    ARID1A mutation
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer (NCT03642067)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Completed
    Last update posted :
    01/28/2025
    Initiation :
    02/12/2019
    Primary completion :
    02/23/2024
    Completion :
    09/18/2024
    PD-L1
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (NCT06769698)
    Phase 2
    Regeneron Pharmaceuticals
    Not yet recruiting
    Last update posted :
    01/10/2025
    Initiation :
    03/26/2025
    Primary completion :
    04/22/2027
    Completion :
    11/28/2029
    PD-L1
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II) (NCT05418972)
    Phase 2
    Melanoma Institute Australia
    Recruiting
    Last update posted :
    01/07/2025
    Initiation :
    08/14/2023
    Primary completion :
    12/01/2025
    Completion :
    12/01/2035
    BRAF
    |
    BRAF mutation • NRAS mutation • NRAS wild-type
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw)
    A Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus Bevacizumab Plus Fluoropyrimidine in Participants With Unresectable or Metastatic Colorectal Cancer (Liberty-201) (NCT05609370)
    Phase 1/2
    BeiGene
    Active, not recruiting
    Last update posted :
    01/01/2025
    Initiation :
    01/29/2023
    Primary completion :
    04/15/2026
    Completion :
    04/15/2026
    PD-L1
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • capecitabine • Avzivi (bevacizumab-tnjn) • alcestobart (LBL-007)
    A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (RELATIVITY-104) (NCT04623775)
    Phase 2
    Bristol-Myers Squibb
    Active, not recruiting
    Last update posted :
    12/20/2024
    Initiation :
    02/17/2021
    Primary completion :
    01/11/2024
    Completion :
    01/30/2026
    PD-L1
    |
    Opdivo (nivolumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • relatlimab (BMS-986016)
    Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma (NCT06295159)
    Phase 2
    H. Lee Moffitt Cancer Center and Research Insti...
    Recruiting
    Last update posted :
    12/17/2024
    Initiation :
    05/17/2024
    Primary completion :
    07/01/2027
    Completion :
    07/01/2027
    PD-L1
    |
    Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer (CA224-056) (NCT04080804)
    Phase 2
    Dan Zandberg
    Recruiting
    Last update posted :
    12/13/2024
    Initiation :
    12/20/2019
    Primary completion :
    05/31/2026
    Completion :
    09/30/2026
    TMB • LAG3
    |
    CD8 positive
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases (CA209-6D9) (NCT05704933)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Active, not recruiting
    Last update posted :
    12/09/2024
    Initiation :
    06/06/2023
    Primary completion :
    06/07/2024
    Completion :
    06/01/2025
    CD8 • PD-1 • IFNG • CD4 • IL2 • IL10
    |
    PD-1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor (NCT03607890)
    Phase 2
    Sidney Kimmel Comprehensive Cancer Center at Jo...
    Recruiting
    Last update posted :
    10/23/2024
    Initiation :
    11/16/2018
    Primary completion :
    10/01/2025
    Completion :
    10/01/2025
    MSI
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    Nivolumab, BMS-936558 in Combination with Relatlimab, BMS-986016 in Patients with Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting (NCT03743766)
    Phase 2
    John Kirkwood
    Completed
    Last update posted :
    09/25/2024
    Initiation :
    03/29/2019
    Primary completion :
    07/03/2024
    Completion :
    07/03/2024
    PD-1 • LAG3
    |
    PD-1 expression • LAG3 expression
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma (NCT05912244)
    Phase 2
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    08/16/2024
    Initiation :
    06/09/2023
    Primary completion :
    06/09/2027
    Completion :
    06/09/2027
    BRAF
    |
    Opdivo (nivolumab) • Cylembio (imsapepimut and etimupepimut, adjuvanted) • Opdualag (nivolumab/relatlimab-rmbw)
    Induction IBI110 and Sintilimab With Chemotherapy In LA HNSCC (NCT06494943)
    Phase 1
    Fudan University
    Active, not recruiting
    Last update posted :
    07/10/2024
    Initiation :
    06/26/2024
    Primary completion :
    12/31/2026
    Completion :
    12/31/2028
    TMB
    |
    paclitaxel • Tyvyt (sintilimab) • IBI110
    Study of INCA32459 a LAG-3 and PD-1 Bispecific Antibody in Participants With Select Advanced Malignancies (NCT05577182)
    Phase 1
    Incyte Corporation
    Recruiting
    Last update posted :
    06/14/2024
    Initiation :
    11/14/2022
    Primary completion :
    04/10/2026
    Completion :
    04/10/2026
    PD-L1
    |
    PD-L1 expression
    |
    INCA32459
    iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer (NCT03867799)
    Phase 2
    Royal Marsden NHS Foundation Trust
    Active, not recruiting
    Last update posted :
    06/14/2024
    Initiation :
    03/27/2019
    Primary completion :
    10/21/2022
    Completion :
    09/01/2024
    EGFR
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors (NCT05629546)
    Phase 1
    Washington University School of Medicine
    Not yet recruiting
    Last update posted :
    06/11/2024
    Initiation :
    06/30/2024
    Primary completion :
    09/30/2028
    Completion :
    06/30/2030
    PD-L1
    |
    Opdivo (nivolumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (NCT03964233)
    Phase 1
    Boehringer Ingelheim
    Active, not recruiting
    Last update posted :
    06/11/2024
    Initiation :
    06/11/2019
    Primary completion :
    09/03/2024
    Completion :
    05/30/2026
    TP53 • MDM2
    |
    TP53 mutation • TP53 wild-type • TP53 amplification
    |
    brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)
    A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma (NCT05419388)
    Phase 1/2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    06/07/2024
    Initiation :
    08/15/2022
    Primary completion :
    10/15/2025
    Completion :
    10/15/2025
    PD-L1 • BRAF
    |
    BRAF mutation • BRAF V600
    |
    tobemstomig (RG6139)
    A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer (NCT05775289)
    Phase 2
    Hoffmann-La Roche
    Recruiting
    Last update posted :
    05/30/2024
    Initiation :
    03/15/2023
    Primary completion :
    03/30/2026
    Completion :
    03/30/2028
    PD-L1
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed • tobemstomig (RG6139)
    A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) (R3767-ONC-2235) (NCT05785767)
    Phase 2/3
    Regeneron Pharmaceuticals
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    06/30/2023
    Primary completion :
    03/11/2030
    Completion :
    02/05/2032
    PD-L1
    |
    Libtayo (cemiplimab-rwlc) • fianlimab (REGN3767)
    Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY) (NCT04082364)
    Phase 2/3
    MacroGenics
    Active, not recruiting
    Last update posted :
    05/15/2024
    Initiation :
    09/30/2019
    Primary completion :
    01/15/2024
    Completion :
    06/01/2025
    PD-L1 • MSI
    |
    PD-L1 expression • HER-2 positive
    |
    Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • Margenza (margetuximab-cmkb) • Zynyz (retifanlimab-dlwr) • tebotelimab (MGD013)
    A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma) (NCT05116202)
    Phase 1/2
    Hoffmann-La Roche
    Completed
    Last update posted :
    05/01/2024
    Initiation :
    02/02/2022
    Primary completion :
    09/22/2023
    Completion :
    03/27/2024
    CD4
    |
    Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • tiragolumab (RG6058) • tobemstomig (RG6139)
    Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies (NCT04370704)
    Phase 1/2
    Incyte Corporation
    Active, not recruiting
    Last update posted :
    04/25/2024
    Initiation :
    07/27/2020
    Primary completion :
    08/04/2025
    Completion :
    08/04/2025
    BRAF
    |
    BRAF mutation
    |
    Zynyz (retifanlimab-dlwr) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)
    Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies (NCT04641871)
    Phase 1
    Symphogen A/S
    Active, not recruiting
    Last update posted :
    04/24/2024
    Initiation :
    10/12/2020
    Primary completion :
    06/01/2024
    Completion :
    06/01/2024
    FGFR2 • IDH1
    |
    IDH1 mutation • FGFR2 mutation • FGFR2 fusion
    |
    irinotecan • S95018 • Sym021 • Sym022
    Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin (CA209-587) (NCT04204837)
    Phase 2
    Salzburger Landeskliniken
    Recruiting
    Last update posted :
    04/18/2024
    Initiation :
    03/06/2017
    Primary completion :
    12/01/2026
    Completion :
    12/01/2027
    PD-L1 • LAG3
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • relatlimab (BMS-986016)
    Neoadjuvant and Adjuvant Checkpoint Blockade (NCT02519322)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    04/05/2024
    Initiation :
    02/02/2016
    Primary completion :
    01/26/2023
    Completion :
    01/26/2023
    PD-L1
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    XmAb23104 (PD1 X ICOS) and XmAb22841 (CTLA-4 X LAG3) in Treating Melanoma Prior Immune Checkpoint Inhibitor Therapy (NCT05695898)
    Phase 1
    University of California, San Francisco
    Active, not recruiting
    Last update posted :
    03/25/2024
    Initiation :
    02/28/2023
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    PD-L1 • BRAF • LAG3
    |
    bavunalimab (XmAb22841) • izuralimab (XmAb23104)
    Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma (Neo-MCC) (NCT06151236)
    Phase 2
    Melanoma Institute Australia
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    03/11/2024
    Primary completion :
    04/01/2026
    Completion :
    04/01/2034
    TMB
    |
    PD-L1 expression
    |
    Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)
    Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG (IMAGINE) (NCT04062656)
    Phase 2
    University Hospital, Essen
    Active, not recruiting
    Last update posted :
    03/11/2024
    Initiation :
    09/26/2019
    Primary completion :
    03/01/2024
    Completion :
    06/01/2025
    LAG3
    |
    LAG3 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • docetaxel • 5-fluorouracil • oxaliplatin • leucovorin calcium • relatlimab (BMS-986016)
    A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer (RELATIVITY-123) (NCT05328908)
    Phase 3
    Bristol-Myers Squibb
    Active, not recruiting
    Last update posted :
    03/01/2024
    Initiation :
    04/28/2022
    Primary completion :
    01/29/2025
    Completion :
    05/31/2028
    PD-L1
    |
    PD-L1 expression • RAS wild-type
    |
    Opdivo (nivolumab) • Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • Opdualag (nivolumab/relatlimab-rmbw)
    Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (NCT05287113)
    Phase 2
    Incyte Biosciences International Sàrl
    Recruiting
    Last update posted :
    02/23/2024
    Initiation :
    11/14/2022
    Primary completion :
    05/21/2024
    Completion :
    09/15/2024
    PD-L1
    |
    PD-L1 expression
    |
    Zynyz (retifanlimab-dlwr) • tuparstobart (INCAGN2385) • verzistobart (INCAGN2390)
    A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients (NCT05787613)
    Phase 2
    Shanghai Henlius Biotech
    Recruiting
    Last update posted :
    02/22/2024
    Initiation :
    07/10/2023
    Primary completion :
    07/01/2025
    Completion :
    07/01/2027
    PD-L1 • ROS1 • LAG3
    |
    PD-L1 expression • ROS1 rearrangement • LAG3 expression
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Hetronifly (serplulimab) • HLX26
    Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy (NCT04326257)
    Phase 2
    Dan Zandberg
    Active, not recruiting
    Last update posted :
    02/07/2024
    Initiation :
    06/05/2020
    Primary completion :
    08/12/2023
    Completion :
    08/12/2024
    LAG3 • CTLA4
    |
    LAG3 expression • CTLA4 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)